



INVITATION CMMC SEMINAR

Sarah Tabrizi

University College London, GB





She led the first successful clinical safety trial of "gene silencing" drug, which reduced the toxic mutant huntingtin protein level in patients, opening up new avenues for HD treatment. Her work is recognized as a benchmark for studies in neurodegenerative diseases.

In her presentation, Tabrizi will provide an overview of the development of new gene therapies for HD and related neurodegenerative disorders,. This will include translational pathways, challenges and opportunities as well as key lessons learned from both successes and failures.

July 02, 2024 at 11.00 a.m.

Lecture Hall, Frauenklinik

Entrance opposite of the CMMC Research Building Robert-Koch-Str. 21, 50931 Cologne

Host:
Michal-Ruth Schweiger
Inst.itute for Translational Epigenetics





Registration & Information